Journal of Cancer Research and Therapeutics Close
 

Figure 2: A 58-year-old, male patient with hepatocellular carcinoma tumor (7.8cm × 6.4cm) located in the S6 who received transarterial chemoembolization (TACE)-MWA treatment. The tumor was shown on a magnetic resonance (MR) image as a T2WI with high signal intensity (a) and verified on a digital subtraction angiography image, and then a TACE was performed (b) a computed tomography (CT) exam was performed 1 day after TACE with iodized oil deposition (c); then MWA was performed with five insertions under CT guidance (d) ablation was considered complete if there is absence of enhancement on MRI image 1 month after ablation (e) and the ablation zone gradually shrunk 6 months after ablation (f) (yellow arrow).

Figure 2: A 58-year-old, male patient with hepatocellular carcinoma tumor (7.8cm × 6.4cm) located in the S6 who received transarterial chemoembolization (TACE)-MWA treatment. The tumor was shown on a magnetic resonance (MR) image as a T2WI with high signal intensity (a) and verified on a digital subtraction angiography image, and then a TACE was performed (b) a computed tomography (CT) exam was performed 1 day after TACE with iodized oil deposition (c); then MWA was performed with five insertions under CT guidance (d) ablation was considered complete if there is absence of enhancement on MRI image 1 month after ablation (e) and the ablation zone gradually shrunk 6 months after ablation (f) (yellow arrow).